Table 2.
Positive control analysis: MR estimates of the effect of genetically proxied GLP-1RAs on T2DM and BMI.
| Outcome | Method | OR (95%CI) | P | Q statistics | P-heterogeneity | Egger intercept | P intercept |
|---|---|---|---|---|---|---|---|
| T2DM | IVW | 0.90 (0.86,0.96) | 0.0004 | 1.4829 | 0.9996 | ||
| MR-Egger | 0.99 (0.84,1.16) | 0.9116 | 0.0604 | 1.0000 | -0.0062 | 0.2605 | |
| Weighted median | 0.89 (0.83,0.96) | 0.0022 | |||||
| Simple mode | 0.89 (0.80,1.00) | 0.0688 | |||||
| Weighted mode | 0.89 (0.80,1.00) | 0.0616 | |||||
| MR-PRESSO | 0.90 (0.89,0.92) | 2.07E-07 | 1.9559 | 0.9993 | |||
| BMI | IVW | 0.94 (0.92,0.96) | 9.78E-08 | 0.5469 | 1.0000 | ||
| MR-Egger | 0.96 (0.90,1.03) | 0.2453 | 0.1218 | 1.0000 | -0.0014 | 0.5291 | |
| Weighted median | 0.94 (0,91,0.97) | 3.78E-05 | |||||
| Simple mode | 0.94 (0.90,0.98) | 0.0205 | |||||
| Weighted mode | 0.94 (0.90,0.98) | 0,0138 | |||||
| MR-PRESSO | 0.94 (0,93,0.94) | 6.98E-12 | 0.6936 | 1.0000 |
MR: Mendelian randomization; T2DM: type 2 diabetes mellitus; BMI: body mass index; GLP-1RAs: glucagon-like peptide-1 receptor agonists; IVW: inverse-variance weighted; MR-PRESSO: Mendelian Randomization Pleiotropy RESidual Sum and Outlier; OR: odds ratio; CI: confidence interval.